About ORIC Pharmaceuticals
ORIC Pharmaceuticals is a publicly listed company based in San Francisco (United States) founded in 2014. Small-molecule drugs are developed for treatment-resistant cancers. It operates on a Professional Services model. ORIC Pharmaceuticals has raised $173.4 million across 8 funding rounds from investors including Fidelity Investments, Pfizer and KKR. The company has 115 employees. Its website oricpharma.com draws about 11 thousand monthly visits. ORIC Pharmaceuticals offers products and services including ORIC-944 and Enozertinib (ORIC-114). Its focus areas include Biotechnology and Oncology. Its legal entity is ORIC Pharmaceuticals, Inc. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
ORIC Pharmaceuticals is dedicated to the discovery and development of innovative therapies aimed at overcoming resistance in cancer treatment. The company targets innate, acquired, and bypass resistance mechanisms to enhance the effectiveness and duration of existing cancer therapies. Operating in the oncology sector, ORIC is engaged in clinical trials for drugs like ORIC-944 for prostate cancer and Enozertinib (ORIC-114) for lung cancer. Solutions are developed through a resistance platform supported by a team of experts in oncology, biology, and medicinal chemistry, with a mission to transform patient lives by addressing significant challenges in cancer treatment.
- Headquarters San Francisco, United States
- Employees 115
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website oricpharma.com
- Social LinkedIn X
- Legal Name Oric Pharmaceuticals, Inc.
- Net Profit-$129.47 M (USD)-1.27as on Dec 31, 2025
- EBITDA-$141.78 M (USD)as on Dec 31, 2025
- Total Equity Funding$173.4M (USD)
in 8 rounds
- Latest Funding Round$125M (USD), Post-IPO
May 2025
- InvestorsFidelity Investments
& 31 more
- Employee Count115
Products & Services of ORIC Pharmaceuticals
ORIC Pharmaceuticals offers a comprehensive portfolio of products and services, including ORIC-944 and Enozertinib (ORIC-114).
A drug targeting resistance in prostate cancer treatment.
A therapy for EGFR/HER2 mutated lung cancer patients.
Funding Insights of ORIC Pharmaceuticals
ORIC Pharmaceuticals has successfully raised a total of $173.4M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $125 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $173.4M
- Total Rounds 8
- Last Round Post-IPO — $125M
- First Round $15.4M
(Oct 2014)
- Investors Count 32
All 8 funding rounds of ORIC Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2025 | $125M | Post-IPO | – | SR One | |
| Jan 2024 | $125M | Post-IPO | – | – | |
| Jul 2023 | $85M | Post-IPO | – | – | |
| Dec 2022 | $25M | Post-IPO | – | – | |
| Aug 2019 | $55M | Series D | – | ArrowMark Partners, Invus | |
| Feb 2018 | $50M | Series C | – | Trinitas Capital Management, Taiho Ventures | |
| Dec 2015 | $53M | Series B | – | Orbimed, ecor1cap | – |
| Oct 2014 | $15.4M | Series A | – | TCG | – |
32 investors in total: 32 institutional.
Investors in ORIC Pharmaceuticals
ORIC Pharmaceuticals has secured backing from 32 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Pfizer and KKR.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Healthcare investment firm focused on novel therapeutics development. | frazierls.com | Palo Alto, United States | ||
Venture capital is provided to healthcare startups by Commodore Capital. | commodorecapital.com | New York, United States | ||
Private investment firm focused on multiple sectors | vikingglobal.com | Greenwich, United States | ||
VC & PE firm focused on healthcare sector | venrockcp.com | Palo Alto, United States | ||
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Early-stage investments in US life science startups are focused on. | 2007 | thecolumngroup.com | San Francisco, United States | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture capital firm and foundation focused on biotech, cleantech, and media & entertainment, education, and more | cityhill.com | San Diego, United States | ||
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States |
Investor details for ORIC Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ORIC Pharmaceuticals
38 people are tracked at ORIC Pharmaceuticals (15 in leadership, 7 in board & advisors, 16 in team); the tracked headcount is 115.
| Name | Role | Group |
|---|---|---|
Matt Panuwat | Chief Business Officer | Leadership |
Dominic Piscitelli | Chief Financial Officer | Leadership |
Lori Friedman | Chief Scientific Officer | Leadership |
Dan Iazzetti | Vice President, Head Of People | Leadership |
Jennifer Shen | Senior Director Regulatory Affairs | Leadership |
Sonia Pawlak | Sr. Director, Pharmsci Program & Alliance Management | Leadership |
Jacob Chacko | CEO | Leadership |
Sandy Koppenol | Director Of Formulation And Drug Delivery | Leadership |
Carmen Breslin | Executive Director | Leadership |
Ajit Narang | Vp, Head Of CMC | Leadership |
Zinnia Xu | Director, Business Development | Leadership |
Alex Pankov | Director, Head Of Bioinformatics | Leadership |
Amanda Albert | Senior Director, Program Management | Leadership |
Elli Chatzopoulou | Director Regulatory Affairs CMC | Leadership |
Pratik Multani | Chief Medical Officer | Leadership |
Richard Heyman | Founder & Chairman Scientific Advisory Board | Board & advisors |
Mardi C. Dier | Board Member | Board & advisors |
Scott Lowe | Founder | Board & advisors |
Charles Sawyers | Founder | Board & advisors |
Lori Kunkel | Board Member | Board & advisors |
18 more people are available in the full profile.
Complete people profiles for ORIC Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of ORIC Pharmaceuticals
ORIC Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol ORIC in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date24 Apr 2020
- Listed onNASDAQ: ORIC
- Listed entityOric Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS68622P1093
- Share price$11.31 (-4.23% on the day) · 2026-10-13
- Market capitalisation$1.17B
- EPS (diluted, trailing year)$-1.35
- Volume (last session)1,158,249
Financials of ORIC Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$129.5M | -$141.8M | |
| 2024 | -$127.8M | -$141.8M | |
| 2023 | -$100.7M | -$109.8M | |
| 2022 | -$89.1M | -$85.8M | |
| 2021 | -$78.7M | -$78.0M |
Detailed financial statements for ORIC Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of ORIC Pharmaceuticals
4 dated milestones of ORIC Pharmaceuticals across 11 years, from founding to its latest funding, stage changes and deals.
- Founded ORIC Pharmaceuticals is founded.
- Funding First funding round of $15.4M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $125.0M.
Competitors of ORIC Pharmaceuticals
ORIC Pharmaceuticals has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of ORIC Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ORIC Pharmaceuticals
The website of ORIC Pharmaceuticals (oricpharma.com) receives about 10.7K visits a month and ranks #1,871,764 among all websites worldwide, #2,557 in Biotechnology and Pharmaceuticals.
- Monthly visits10.7K
▼ 13.9% vs previous month
- Unique visitors5.1K
per month
- Global rank#1,871,764
among all websites
- Category rank#2,557
Health · Biotechnology and Pharmaceuticals
- Bounce rate34%
- Pages per visit1.8
- Average visit21 sec
- DevicesDesktop 45% · Mobile 55%
Websites whose visitors overlap most with ORIC Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| personalis.com | 100% | 15K | #748,077 | View details | |
onclive.com | onclive.com | 50% | #306,443 | – | |
annalsofoncology.org | annalsofoncology.org | 50% | #169,085 | – | |
| yalemedicine.org | 50% | #65,820 | View details |
Top companies in Oncology
3 companies that operate in the same segment as ORIC Pharmaceuticals (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Oric Pharmaceuticals
Complete news archive for ORIC Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ORIC Pharmaceuticals
ORIC Pharmaceuticals was founded in 2014.
ORIC Pharmaceuticals is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
ORIC Pharmaceuticals is a funded company, having raised a total of $173.4M across 8 funding rounds to date. The company's 1st funding round was a Series A of $15.4M, raised on Oct 2014.
ORIC Pharmaceuticals has 115 employees.
ORIC Pharmaceuticals is dedicated to the discovery and development of innovative therapies aimed at overcoming resistance in cancer treatment. The company targets innate, acquired, and bypass resistance mechanisms to enhance the effectiveness and duration of existing cancer therapies. Operating in the oncology sector, ORIC is engaged in clinical trials for drugs like ORIC-944 for prostate cancer and Enozertinib (ORIC-114) for lung cancer. Solutions are developed through a resistance platform supported by a team of experts in oncology, biology, and medicinal chemistry, with a mission to transform patient lives by addressing significant challenges in cancer treatment.
ORIC Pharmaceuticals offers ORIC-944 and Enozertinib (ORIC-114).
Yes, ORIC Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol ORIC.
ORIC Pharmaceuticals has 32 investors. Key investors include Fidelity Investments, Pfizer, KKR, NexTech AR Solutions, and Memorial Sloan - Kettering Cancer Center.
ORIC Pharmaceuticals operates through Oric Pharmaceuticals, Inc..